blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2361629

EP2361629 - Prevention and treatment of synucleinopathic disease [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  03.09.2021
Database last updated on 24.04.2024
FormerGrant of patent is intended
Status updated on  13.12.2020
FormerExamination is in progress
Status updated on  27.11.2020
FormerGrant of patent is intended
Status updated on  13.04.2020
FormerExamination is in progress
Status updated on  30.03.2020
FormerGrant of patent is intended
Status updated on  04.08.2019
FormerExamination is in progress
Status updated on  17.07.2019
FormerGrant of patent is intended
Status updated on  21.02.2019
FormerExamination is in progress
Status updated on  10.01.2019
FormerGrant of patent is intended
Status updated on  10.05.2018
FormerExamination is in progress
Status updated on  27.04.2018
FormerGrant of patent is intended
Status updated on  14.12.2017
FormerExamination is in progress
Status updated on  28.11.2017
FormerGrant of patent is intended
Status updated on  17.07.2017
FormerExamination is in progress
Status updated on  09.12.2016
Most recent event   Tooltip03.09.2021Application deemed to be withdrawnpublished on 06.10.2021  [2021/40]
Applicant(s)For all designated states
Janssen Alzheimer Immunotherapy
Airton Road
Tallaght
Dublin 24 / IE
For all designated states
The Regents of the University of California
1111 Franklin Street, 5th Floor
Oakland, CA 94607 / US
[2019/36]
Former [2017/33]For all designated states
Janssen Alzheimer Immunotherapy
Airton Road
Tallaght
Dublin 24 / IE
For all designated states
The Regents of The University of California Santa Cruz
1111 Franklin Street, 5th Floor
Oakland, CA 94607 / US
Former [2014/36]For all designated states
Janssen Alzheimer Immunotherapy
Airton Road
Tallaght
Dublin 24 / IE
For all designated states
The Regents of the University of California
1111 Franklin Street, 12th Floor
Oakland, CA 94607 / US
Former [2012/02]For all designated states
Janssen Alzheimer Immunotherapy
Little Island Industrial Estate
Little Island, County Cork / IE
For all designated states
The Regents of the University of California
1111 Franklin Street
Oakland, California 94607 / US
Former [2011/35]For all designated states
Elan Pharmaceuticals Inc.
800 Gateway Boulevard
South San Francisco, CA 94080 / US
For all designated states
The Regents of the University of California
1111 Franklin Street
Oakland, California 94607 / US
Inventor(s)01 / Schenk, Dale B.
1542 Los Altos Drive
Burlingame CA California 94010 / US
02 / Masliah, Eliezer
4661 Corte Mar Corazon
San Diego CA California 92130 / US
[N/P]
Former [2011/35]01 / Schenk, Dale B.
1542 Los Altos Drive
Burlingame, CA 94010 / US
02 / Masliah, Eliezer
4661 Corte Mar Corazon
San Diego, CA 92130 / US
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2011/35]Goodfellow, Hugh Robin
Carpmaels & Ransford One Southampton Row
London WC1B 5HA / GB
Application number, filing date11164647.731.10.2003
[2011/35]
Priority number, dateUS20020423012P01.11.2002         Original published format: US 423012 P
[2011/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2361629
Date:31.08.2011
Language:EN
[2011/35]
Search report(s)(Supplementary) European search report - dispatched on:EP03.08.2011
ClassificationIPC:A61K38/17, A61K39/00, A61P25/16
[2011/35]
CPC:
A61K39/0007 (EP,US); A61K38/1709 (EP,US); A61K45/06 (EP,US);
A61K51/1078 (EP,US); A61P25/00 (EP); A61P25/16 (EP);
A61P25/28 (EP); A61P37/04 (EP); A61P43/00 (EP);
A61K2039/55566 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2011/35]
TitleGerman:Prävention und Behandlung von synucleinopathischer Erkrankung[2011/35]
English:Prevention and treatment of synucleinopathic disease[2011/35]
French:Prévention et traitement d'une maladie synucleopathique[2011/35]
Examination procedure29.02.2012Amendment by applicant (claims and/or description)
29.02.2012Examination requested  [2012/20]
12.12.2016Despatch of a communication from the examining division (Time limit: M06)
20.06.2017Reply to a communication from the examining division
18.07.2017Communication of intention to grant the patent
28.11.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
15.12.2017Communication of intention to grant the patent
24.04.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
11.05.2018Communication of intention to grant the patent
08.01.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
22.02.2019Communication of intention to grant the patent
04.07.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
05.08.2019Communication of intention to grant the patent
30.03.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
14.04.2020Communication of intention to grant the patent
25.11.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
14.12.2020Communication of intention to grant the patent
27.04.2021Application deemed to be withdrawn, date of legal effect  [2021/40]
20.05.2021Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2021/40]
Parent application(s)   TooltipEP03783083.3  / EP1578253
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20030783083) is  11.10.2010
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
25.11.2020Request for further processing filed
25.11.2020Full payment received (date of receipt of payment)
Request granted
04.12.2020Decision despatched
The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
30.03.2020Request for further processing filed
30.03.2020Full payment received (date of receipt of payment)
Request granted
08.04.2020Decision despatched
The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
08.01.2019Request for further processing filed
08.01.2019Full payment received (date of receipt of payment)
Request granted
29.01.2019Decision despatched
Fees paidRenewal fee
03.05.2011Renewal fee patent year 03
03.05.2011Renewal fee patent year 04
03.05.2011Renewal fee patent year 05
03.05.2011Renewal fee patent year 06
03.05.2011Renewal fee patent year 07
03.05.2011Renewal fee patent year 08
11.10.2011Renewal fee patent year 09
11.10.2012Renewal fee patent year 10
14.10.2013Renewal fee patent year 11
14.10.2014Renewal fee patent year 12
12.10.2015Renewal fee patent year 13
11.10.2016Renewal fee patent year 14
11.10.2017Renewal fee patent year 15
26.04.2019Renewal fee patent year 16
15.10.2019Renewal fee patent year 17
14.10.2020Renewal fee patent year 18
Penalty fee
Additional fee for renewal fee
31.10.201816   M06   Fee paid on   26.04.2019
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO0072876  (NEURALAB LTD [US], et al) [A] 1-15 * abstract * * page 4, line 24 - page 5, line 19 * * page 8, line 8 - page 9, line 3; examples 1,2,4,5,7,13,16; sequences 7-11 * * claims 12,18-21 *;
 [Y]WO0160794  (UNIV CALIFORNIA [US], et al) [Y] 1-5 * abstract * * page 4, line 24 - page 5, line 19 * * page 8, line 8 - page 9, line 3; examples 1,2,4,5,7,13,16 * * claims 12,18-21 *;
 [A]US2002151464  (WOLOZIN BENJAMIN [US], et al) [A] 1-15 * abstract * * page 3, paragraphs [0032]-[0033] * * page 4, paragraph [0035] - page 5, paragraph [0041]; examples 8,9 * * claims 16-51 *;
 [AP]WO03000714  (PANACEA PHARMACEUTICALS INC [US], et al) [AP] 1-15 * abstract * * page 3, paragraphs 6,7 ** page 5, paragraph 14 - page 6, paragraph 20; claims 1,3,9,11,13 *;
 [AP]WO03045128  (UNIV NEW YORK [US], et al) [AP] 1-15 * abstract * * page 1, paragraph 3 - page 2, paragraph 3 * * page 29, paragraph 45 - page 32, paragraph 49 * * page 38, paragraph 46 - page 39, paragraph 46 * * page 58, paragraph 111 - page 60, paragraph 114 * * page 77, paragraph 114 - page 82, paragraph 153; claims 89-103 *;
 [Y]  - BARD F ET AL, "Peripherally administered antibodies against amyloid beta- peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (20000801), vol. 6, no. 8, ISSN 1078-8956, pages 916 - 919, XP002154518 [Y] 1-5 * abstract * * page 174, column R, lines 4-7 * * page 177, column L, paragraph 3 - column R, paragraph 1; table 1 *

DOI:   http://dx.doi.org/10.1038/78682
 [YD]  - SCHENK D ET AL, "Immunization with amyloid-beta attenuates Alzheimer -disease-like pathology in the PDAPP mouse [see comments]", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, (19990708), vol. 400, no. 6740, ISSN 0028-0836, pages 173 - 177, XP002154168 [YD] 1-5 * abstract * * page 916, column R, paragraph L - page 917, column R, paragraph 1 *

DOI:   http://dx.doi.org/10.1038/22124
 [A]  - HASHIMOTO M ET AL, "[beta]-synuclein inhibits [alpha]-synuclein aggregation: A possible role as an anti-Parkinsonian factor", NEURON 20011025 US, (20011025), vol. 32, no. 2, ISSN 0896-6273, pages 213 - 223, XP002497157 [A] 1-15 * abstract * * page 213 * * page 216, column L, paragraph 1 - page 218, column R, paragraph 1 * * page 219, column L, paragraph 1 - column R, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/S0896-6273(01)00462-7
 [A]  - WINDISCH M ET AL, "Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory [beta]-synuclein-derived peptides", JOURNAL OF MOLECULAR NEUROSCIENCE 200208 US, (200208), vol. 19, no. 1-2, ISSN 0895-8696, pages 63 - 69, XP002497158 [A] 1-15 * abstract * * page 66, column L, paragraph 1 - page 67, column L, paragraph 3; figure 2 *

DOI:   http://dx.doi.org/10.1007/s12031-002-0012-8
 [YD]  - MASLIAH ELIEZER ET AL, "beta-Amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, (20011009), vol. 98, no. 21, ISSN 0027-8424, pages 12245 - 12250, XP002201752 [YD] 1-5 * abstract * * page 12245, column R, paragraph 2 * * page 12248, column R, paragraph 3 - page 12250, column R, paragraph 1 *

DOI:   http://dx.doi.org/10.1073/pnas.211412398
 [A]  - WANKER E E, "Protein aggregation in Huntington's and Parkinson's disease: Implications for therapy", MOLECULAR MEDICINE TODAY 2000 GB, (2000), vol. 6, no. 10, ISSN 1357-4310, pages 387 - 391, XP002497160 [A] 1-15 * abstract * * page 387 * * page 390, column L, paragraph 2 - column R, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/S1357-4310(00)01761-5
 [A]  - LECERF J-M ET AL, "Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, (20010410), vol. 98, no. 8, ISSN 0027-8424, pages 4764 - 4769, XP002323805 [A] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1073/pnas.071058398
 [A]  - HEISER V ET AL, "Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, (20000606), vol. 97, no. 12, ISSN 0027-8424, pages 6739 - 6744, XP002155981 [A] 1-15 * abstract * * page 6744, column L, line 2 - column R, paragraph L *

DOI:   http://dx.doi.org/10.1073/pnas.110138997
 [A]  - SIGURDSSON E M ET AL, "Immunization delays the onset of prion disease in mice", AMERICAN JOURNAL OF PATHOLOGY 2002 US, (200207), vol. 161, no. 1, ISSN 0002-9440, pages 13 - 17, XP002497161 [A] 1-15 * abstract * * page 15, column R, paragraph 1 - page 16, column R, paragraph 1 *
by applicantUS4634664
 US4634666
 US4666829
 US4855283
 GB2220211
 EP0378881
 WO9007861
 WO9014837
 EP0427347
 WO9110741
 US5057540
 WO9117271
 WO9118980
 WO9201047
 WO9220791
 WO9222653
 WO9301222
 US5196512
 WO9306121
 US5208036
 US5225539
 US5229490
 US5264618
 US5279833
 US5283185
 WO9408051
 US5304489
 WO9412629
 WO9505853
 US5399346
 WO9507707
 WO9512608
 WO9530642
 WO9535503
 US5530101
 US5545806
 US5565332
 US5569825
 WO9634625
 US5585089
 US5593970
 US5612486
 US5625126
 WO9717613
 WO9717614
 US5633425
 US5643576
 US5661016
 US5693762
 US5693761
 US5733743
 US5736142
 US5741957
 WO9823635
 WO9825386
 US5770429
 US5789650
 WO9840100
 US5814318
 US5837242
 US5849992
 WO9859050
 US5858657
 US5871907
 US5874299
 US5877397
 US5877218
 WO0072880
 WO0160794
    - MCKEITH ET AL., "Clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the CDLB International Workshop", NEUROLOGY, (1996), vol. 47, pages 1113 - 24
    - GALASKO ET AL., "Clinical-neuropathological correlations in Alzheimer's disease and related dementias", ARCH. NEUROL., (1994), vol. 51, pages 888 - 95
    - TANNER ET AL., "Epidemiology of Parkinson's disease and akinetic syndromes", CURR. OPIN. NEUROL., (2000), vol. 13, pages 427 - 30
    - SPILLANTINI ET AL., NATURE, (1997), vol. 388, pages 839 - 40
    - TAKEDA ET AL., AM J. PATHOL., (1998), vol. 152, pages 367 - 72
    - WAKABAYASHI ET AL., NEUROSCI. LETT., (1997), vol. 239, pages 45 - 8
    - KRUGER ET AL., NATURE GEN., (1998), vol. 18, pages 106 - 8
    - POLYMEROPOULOS MH ET AL., SCIENCE, (1997), vol. 276, pages 2045 - 7
    - MASLIAH ET AL., SCIENCE, (2000), vol. 287, pages 1265 - 9
    - FEANY ET AL., NATURE, (2000), vol. 404, pages 394 - 8
    - IWAI A., BIOCHIM. BIOPHYS. ACTA, (2000), vol. 1502, pages 95 - 109
    - MASLIAH ET AL., AM J. PATHOL, (1996), vol. 148, pages 201 - 10
    - UEDA ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 11282 - 6
    - HASIMOTO ET AL., "Alpha-Synuclein in Lewy body disease and Alzheimer's disease", BRAIN PATHOL, (1999), vol. 9, pages 707 - 20
    - DJALDETTI ET AL., "New therapies for Parkinson's disease", J. NEUROL, (2001), vol. 248, pages 35 7 - 62
    - KIRIK ET AL., "Long-term rAA V-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system", J. NEUROSCI, (2000), vol. 20, pages 4686 - 4700, XP000972996
    - SCHENK ET AL., "Immunization with amyloid-? attenuates Alzheimer-disease-like pathology in PDAPP mouse", NATURE, (1999), vol. 408, doi:doi:10.1038/22124, pages 173 - 177, XP002154168

DOI:   http://dx.doi.org/10.1038/22124
    - MORGAN ET AL., "A-beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease", NATURE, (2000), vol. 408, doi:doi:10.1038/35050116, pages 982 - 985, XP002266055

DOI:   http://dx.doi.org/10.1038/35050116
    - JANUS ET AL., "A-beta peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease", NATURE, (2000), vol. 408, doi:doi:10.1038/35050110, pages 979 - 82, XP002969677

DOI:   http://dx.doi.org/10.1038/35050110
    - SMITH, WATERMAN, ADV. APPL. MATH., (1981), vol. 2, page 482
    - NEEDLEMAN, WUNSCH, J. MOL. BIOL., (1970), vol. 48, page 443
    - PEARSON, LIPMAN, PROC. NAT'L. ACAD. SCI. USA, (1988), vol. 85, page 2444
    - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410
    - HENIKOFF, HENIKOFF, PROC. NATL. ACAD. SCI. USA, (1989), vol. 89, page 10915
    - SONGSIVILAI, LACHMANN, CLIN. EXP. IMMUNOL., (1990), vol. 79, pages 315 - 321
    - KOSTELNY, J IMMUNOL., (1992), vol. 148, pages 1547 - 1553
    - KANG ET AL., NATURE, (1987), vol. 325, page 773
    - PONTE ET AL., NATURE, (1988), vol. 331, page 525
    - KITAGUCHI ET AL., NATURE, (1988), vol. 331, page 530
    - Epitope Mapping Protocols in Methods in Molecular Biology, (1996), vol. 66
    - BURKE ET AL., J. INF. DIS., (1994), vol. 170, pages 1110 - 19
    - TIGGES, J. IMMUNOL., vol. 156, pages 3901 - 3910
    - STAHLI ET AL., METHODS IN ENZYMOLOGY, (1983), vol. 9, pages 242 - 253
    - KIRKLAND ET AL., J. IMMUNOL., (1986), vol. 137, pages 3614 - 3619
    - MOREL ET AL., MOLEC. IMMUNOL., (1988), vol. 25, no. 1, pages 7 - 15
    - CHEUNG ET AL., VIROLOGY, (1990), vol. 176, pages 546 - 552
    - MOLDENHAUER, SCAND. J. IMMUNOL., (1990), vol. 32, pages 77 - 82
    - UEDA ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1993), vol. 90, no. 23, pages 11282 - 11286
    - IWAI ET AL., BIOCHEMISTRY, vol. 34, pages 10139 - 10145
    - JENSEN ET AL., BIOCHEM. J., (1995), vol. 31U, pages 91 - 94
    - UéDA ET AL., PNAS USA, (1993), vol. 90, pages 11282 - 11286
    - Essential Immunology, BLACKWELL SCIENTIFIC PUBLICATIONS, page 181
    - MASLIAH ET AL., SCIENCE, (2000), vol. 287, pages 1265 - 1269
    - VAN DER PUTTER ET AL., J. NEUROSCIENCE, (2000), vol. 20, pages 6025 - 6029
    - GAMES ET AL., NATURE, (1995), vol. 373, page 523
    - HSIAO ET AL., SCIENCE, (1996), vol. 274, page 99
    - STAUFENBIEL ET AL., PROC. NATL. ACAD. SCI. USA, (1997), vol. 94, pages 13287 - 13292
    - STURCHLER-PIERRAT ET AL., PROC. NATL. ACAD. SCI. USA, (1997), vol. 94, pages 13287 - 13292
    - BORCHELT ET AL., NEURON, (1997), vol. 19, pages 939 - 945
    - M. FLINT BEAL, NATURE REVIEWS NEUROSCIENCE, (2001), vol. 2, pages 325 - 334
    - ARIMA ET AL., BRIAN RES., (1998), vol. 808, pages 93 - 100
    - CROWTHER ET AL., NEUROSCIENCE LETT., (2000), vol. 292, pages 128 - 130
    - SPILLANTINI ET AL., NATURE, (1997), vol. 388, pages 839 - 840
    - H. SHIMURA ET AL., SCIENCE, (20010713), vol. 293, no. 5528, pages 224 - 5
    - CHOTHIA, LESK, J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - CHOTHIA ET AL., NATURE, (1989), vol. 342, pages 878 - 883
    - QUEEN ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, pages 10029 - 10033
    - OESTBERG ET AL., HYBRIDOMA, (1983), vol. 2, pages 361 - 367
    - NATURE, (1994), vol. 148, pages 1547 - 1553
    - NATURE BIOTECHNOLOGY, (1996), vol. 14, page 826
    - HUSE ET AL., SCIENCE, (1989), vol. 246, pages 1275 - 1281
    - QUEEN ET AL., IMMUNOL. REV., (1986), vol. 89, page 49
    - CO ET AL., J. IMMUNOL., (1992), vol. 148, page 1149
    - SINIGAGLIA F. ET AL., NATURE, (1988), vol. 336, pages 778 - 780
    - CHICZ R.M. ET AL., J. EXP. MED., (1993), vol. 178, pages 27 - 47
    - HAMMER J. ET AL., CELL, (1993), vol. 74, pages 197 - 203
    - FALK K. ET AL., IMMUNOGENETICS, (1994), vol. 39, pages 230 - 242
    - SOUTHWOOD S. ET AL., J IMMUNOLOGY, (1998), vol. 160, pages 3363 - 3373
    - ALEXANDER J ET AL., IMMUNIG, (1994), vol. 1, pages 751 - 761
    - IMMUN. REV., (1982), vol. 62, page 185
    - LAWRIE, TUMIN, CUR. OPIN. GENET. DEVELOP., (1993), vol. 3, pages 102 - 109
    - BETT ET AL., J. VIROL., (1993), vol. 67, page 5911
    - ZHOU ET AL., J. EXP. MED., (1994), vol. 179, page 1867
    - DUBENSKY ET AL., J. VIROL., (1996), vol. 70, pages 508 - 519
    - OHE ET AL., HUMAN GENE THERAPY, (1995), vol. 6, pages 325 - 333
    - XIAO, BRANDSMA, NUCLEIC ACIDS. RES., (1996), vol. 24, pages 2630 - 2622
    - GLENNER, WONG, BIOCHEM. BIOPHYS. RES. COMMUN., (1984), vol. 120, page 1131
    - HARDY, TINS, (1997), vol. 20, page 154
    - HARDY ET AL., TINS, (1997), vol. 20, pages 155 - 158
    - STOUTE ET AL., N. ENGL. J. MED., (1997), vol. 336, pages 86 - 91
    - CHANG ET AL., ADVANCED DRUG DELIVERY REVIEWS, (1998), vol. 32, pages 173 - 186
    - LANGER, SCIENCE, (1990), vol. 249, page 1527
    - HANES, ADVANCED DRUG DELIVERY REVIEWS, (1997), vol. 28, pages 97 - 119
    - GLENN ET AL., NATURE, (1998), vol. 391, page 851
    - PAUL ET AL., EUR. J. IMMUNOL., (1995), vol. 25, pages 3521 - 24
    - CEVC ET AL., BIOCHEM. BIOPHYS. ACTA, (1998), vol. 1368, pages 201 - 15
    - HSUE ET AL., AM. J. PATHOL., (2000), vol. 157, pages 401 - 410
    - IWAI, NEURON, (1995), vol. 14, page 467
    - MASLIAH ET AL., AM. J. PATHOL, (1996), vol. 148, pages 201 - 10
    - MASLIAH ET AL., PNAS USA, (2001), vol. 98, pages 12245 - 12250
 US20020423012
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.